I can see where you are coming from ... the key is " moving to mass production". It may be that they simply couldn't make the financials work without re-engineering/re-designing, and they turned to IBM for part of the solution to this. . If this is the case it's a terrible blow for Sensera ... let's hope that AbioMed and the OneTouch CGM go gangbusters. We await news & confirmation from Sensera.
SE1 Price at posting:
3.6¢ Sentiment: Buy Disclosure: Held
